Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer.
Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study (NCT03447769) of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer (NSCLC). Garon presented the results during the 2022 European Society for Medical Oncology Congress.
CANOPY-A failed to meet its primary end point according to Garon, however, there was a numerical advantage in the canakinumab arm compared with placebo. The DFS in the canakinumab arm was 30.0% vs 31.6% with placebo. The median DFS was 35.0 months in the canakinumab arm vs 29.7 months in the placebo arm (HR 0.94; 95% CI 0.78-1.14; one-sided P =0.258).
Across predefined subgroups of patients, there was also no meaningful difference in DFS with canakinumab compared with placebo.
0:08 | The primary endpoint, which was disease-free survival was not positive, although numerically it did favor canakinumab, particularly at the median. The p value was one-sided and was 0.26, reflecting the similarity of the curves throughout the entirety of the curve with a hazard ratio that was not particularly impressive. In addition, when we looked for different subgroups, we really were not able to find subgroups where the 95% confidence interval excluded 1 and so as a result, this is a study that really was not able to show the value of canakinumab in the setting of completely resected non–small cell lung cancer.